2 active not recruiting, 2 completed, 1 recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
Follow Inventprise Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults IVT Shigella-04, Placebo (0.9% saline) - Shigella, Diarrhea | Phase 1 | Recruiting | Inventprise Inc. | 60 | 2025-10-09 | 2025-11-19 |
| Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants Formulation B, Formulation C, Formulation D - Pneumococcal Disease, Invasive | Phase 2 | Active not recruiting | Inventprise Inc. | 421 | 2025-01-27 | 2025-09-02 |
| Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age. IVT GBS-06, Placebo - Group B Streptococcal Infections | Phase 1 / Phase 2 | Active not recruiting | Inventprise Inc. | 600 | 2024-11-12 | 2025-11-18 |
| Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine IVT PCV-25 Formulation A, IVT PCV-25 Formulation B, IVT PCV-25 Formulation C - Pneumococcal Vaccines | Phase 2 | Completed | Inventprise Inc. | 220 | 2023-10-25 | 2026-03-17 |
| Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine IVT PCV-25, PCV 20 - Pneumococcal Vaccines | Phase 1 | Completed | Inventprise Inc. | 65 | 2022-09-28 | 2023-08-30 |
Diarrhea (1) · Dysentery, Bacillary (1) · Pneumococcal Infections (1) · Streptococcal Infections (1)
D-Worm (1) · Sodium Chloride (1)
Canada (2) · United States (2) · Philippines (1) · South Africa (1)
Sybil Tasker, MD, MPH, FIDSA (2) · Joanne Langley, MD, MSc, FRCPC (1)